For the treatment of hospital-acquired pneumonia/ ventilator associated pneumonia caused by Gram-negative bacteria: ZAVICEFTA (ceftazidime and avibactam)

Pfizer has a strong portfolio in licensed products for the treatment of pneumonia, including ZAVICEFTA® (ceftazidime and avibactam) and ZINFORO® (ceftaroline fosamil).*†1,2 ZAVICEFTA® is indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)1.

Clinical Information

Useful Resources

HAP/VAP is:

  • A frequent cause of mortality, with rates ranging from approximately 20-70% 3,4
  • Predominantly caused by increasingly resistant aerobic Gram-negative bacteria which are difficult to treat 5-9

ZAVICEFTA: an antipseudomonal cephalosporin combined with a novel β-lactamase inhibitor, with bactericidal activity against difficult-to-treat infections due to aerobic Gram-negative bacteria frequently encountered in HAP/VAP, including:10-14

  • Pseudomonas aeruginosa (including many ceftazidime- resistant strains)
  • ESBL-producing Enterobacteriaceae
  • Carbapenem-resistant Enterobacteriaceae

Footnotes:

*ZAVICEFTA® is indicated for the treatment of the following infections in adults: Complicated urinary tract infections, including pyelonephritis; Complicated intra-abdominal infections; Hospital-acquired pneumonia, including ventilator-associated pneumonia; Infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.1

†Zinforo® is indicated for the treatment of patients with complicated skin and soft tissue infections and community-acquired pneumonia.2

Abbreviations:

ESBL, extended-spectrum b-lactamase; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia.

References:

1.ZAVICEFTA. Summary of Product Characteristics; 2. ZINFORO. Summary of Product Characteristics; 3. American Thoracic Society; Infectious Diseases Society of America. Am J Respir Crit Care Med 2005;171:388–416; 4. Chastre J, Fagon J-Y. Am J Respir Crit Care Med 2002;165:867–903; 5.  Jones RN. Clin Infect Dis 2010;51 (Suppl 1):S81–7; 6. Brusselaers N, et al. Ann Intensive Care 2011;1:47; 7. Centers for Disease Control and Prevention (CDC). Gram-negative bacteria infections in healthcare settings. Available at: https://www.cdc.gov/hai/organisms/gram-negative-bacteria.html  (last accessed April 2020); 8. Bush K. Crit Care 2010;14:224; 9. Ventola CL. P T 2015;40:277–83; 10. Torres A, et al. Lancet Infect Dis 2017 Dec 15; doi 10.1016/S1473–3099(17)30747–8 [Epub]; 11. Torres A, et al. Lancet Infect Dis 2017 Dec 15; doi 10.1016/S1473–3099(17)30747–8 [Epub] (supplementary appendix); 12. de Jonge BLM, et al. Antimicrob Agents Chemother 2016;60:3163–9; 13. Hackel M, et al. Antimicrob Agents Chemother 2016;60:4677–83; 14. Karlowsky J, et al. Antimicrob Agents Chemother 2016;60:2849–57

Prescribing Information
Meronem IV 1g – SPC 
Legal Category: POM.       Basic NHS Cost: 10 vial pack £206.28
Meronem IV 500mg – SPC 
Legal Category: POM.       Basic NHS Cost: 10 vial pack £103.14

 

Piperacillin/tazobactam
Tazocin 2 g/0.25 g Powder for Solution for Infusion – SPC
Legal category: POM.       Basic NHS cost: 1 vial pack £7.65 
Tazocin 4  g/0.5 g Powder for Solution for Infusion – SPC
Legal category: POM.       Basic NHS cost: 1 vial pack £15.17 
 
Tygacil 50 mg Powder for Solution for Infusion – SPC
Legal Category: POM.       Basic NHS Cost: 10 vial pack £323.10
 
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM.       Basic NHS price: 10 vial pack £857.00.

PP-ZVA-GBR-0996.  October 2020